Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 4:8:1203.
doi: 10.3389/fimmu.2017.01203. eCollection 2017.

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

Stefan H E Kaufmann  1 , Hazel M Dockrell  2 , Nick Drager  3 , Mei Mei Ho  4 , Helen McShane  5 , Olivier Neyrolles  6 , Tom H M Ottenhoff  7 , Brij Patel  8 , Danielle Roordink  3 , François Spertini  9 , Steffen Stenger  10 , Jelle Thole  3 , Frank A W Verreck  11 , Ann Williams  12 ; TBVAC2020 Consortium
Collaborators, Affiliations
Review

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development

Stefan H E Kaufmann et al. Front Immunol. .

Abstract

TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.

Keywords: bacille Calmette–Guérin; biomarker; clinical trial; discovery; portfolio management; tuberculosis; vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of the TBVAC2020 project structure indication interactions between WorkPackages (WPs) and flow from discovery via preclinical testing to clinical trial of most promising vaccine candidates.
Figure 2
Figure 2
Schematic representation of research priorities and connectivity in WorkPackage 5.
Figure 3
Figure 3
TBVI vaccine pipeline, overview of the current tuberculosis (TB) vaccine candidates in the development pipeline, per text box: acronym vaccine candidate, development partners.
Figure 4
Figure 4
TBVAC2020 management infrastructure.
See this image and copyright information in PMC

References

    1. Calmette A. Sur la vaccination préventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann Institut Pasteur (1927) 41(3):201–32.
    1. WHO. Report on the Global Tuberculosis Epidemic 1998. Geneva: World Health Organization; (1998).
    1. Kaufmann SH, Evans TG, Hanekom WA. Tuberculosis vaccines: time for a global strategy. Sci Transl Med (2015) 7(276):276fs8. 10.1126/scitranslmed.aaa4730 - DOI - PubMed
    1. Kaufmann SH, Weiner J, Von Reyn CF. Novel approaches to tuberculosis vaccine development. Int J Infect Dis (2017) 56:263–7. 10.1016/j.ijid.2016.10.018 - DOI - PubMed
    1. Kaufmann SH, Weiner JR, Maertzdorf J. Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers. Expert Rev Vaccines (2017) 16(8):845–53. 10.1080/14760584.2017.1341316 - DOI - PubMed